CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ankyra is pleased to announce the appointment of Dr. Julia G. Butchko and Ms. Tara Withington to the Board of Directors effective September 25, 2024. They will both serve as independent board members and their appointment brings the total board composition to seven directors. “We are delighted to welcome Dr. Butchko and Ms. Withington to the Board”, stated Tillman Gerngross, PhD, Chairman of the Ankyra Board of Directors. “These accomplished individuals bring a fresh perspective to Ankyra at a critical time in the company’s growth.” Howard L. Kaufman, MD, President and Chief Executive Officer at Ankyra added “I am especially enthusiastic about working with Dr. Butchko and Ms. Withington since they bring considerable strengths in research and development as well as representing the patient perspective as we pursue our mission of delivering new drugs to patients with cancer.”
Julia G. Butchko, Ph.D. brings 25 years of industry experience and most recently served as Chief Development Officer at Immunovant (NASDAQ: IMVT), a biopharmaceutical company focused on developing therapies for patients with autoimmune disease. Dr. Butchko joined Immunovant in October 2019 and has co-led Research and Development to advance batoclimab (IMVT-1401) from early development to multiple, global registration trials and IMVT-1402 from candidate identification through registration trial planning. Prior to Immunovant, Dr. Butchko held various leadership roles at Eli Lilly and Company where she most recently served as the Chief of Staff, Strategy and Operations for Lilly’s Immunology and Neuroscience businesses and Vice President, Lilly Oncology Portfolio Management and Clinical Development. Dr. Butchko earned a B.S. in Chemistry from the State University of New York at Fredonia, a Ph.D. in Chemistry from Pennsylvania State University, and a Business Certificate from Indiana University, Kelly School of Business. Dr. Butchko stated that “I am delighted to be joining Ankyra’s Board of Directors at this exciting time. This year will be an impactful one for the Company as the ANK-101 Phase 1 program expands, and the Company advances discovery and early development efforts. I believe Ankyra’s anchoring technology holds a breadth of potential to improve the treatment for cancer patients and look forward to working with the senior leadership team as the Company continues to grow.”
Tara Withington has over 40 years’ executive experience serving the nonprofit sector. Currently she is a principal and Vice President with Executive Director, Incorporated (EDI), an association management company that manages more than 40 scientific organizations and professional boards. She takes special interest in improving organizational excellence, including board development and infrastructure improvement. She also has a keen ability to forecast influences impacting associations and offers innovative ideas and an entrepreneurial mindset to position organizations to take advantage of opportunities and identify challenges allowing organizations to pivot for optimal outcomes. She has previously served as executive director or consulting partner for over 20 organizational boards. Ms. Withington served as a member of the Board of Directors for the AMC Institute and is a member in good standing in the American Society of Association Executives (ASAE), where she currently serves as a member of the Foresight Advisory Task Force. In 2001, the Society for Immunotherapy of Cancer (SITC) joined EDI and Ms. Withington began her tenure as the Executive Director and principal staff member. Tara has been instrumental in positioning the society as a universally respected organization known for its dedication to advancing the science and application of cancer immunotherapy both in the US and abroad. Ms. Withington holds a degree in Business Management as well as the Certified Association Executive (CAE) designation. In 2020 she received the Society for Immunotherapy of Cancer inaugural Lifetime Achievement Award. She currently serves as the Executive Director Emeritus of SITC Ms. Withington states “I am especially pleased to be joining the Board at Ankyra at this exciting time in their development.” She added that immunotherapy “offers a chance for durable responses and better patient experience, and I share the Ankyra team’s vision of providing new drugs for patients with cancer while ensuring broad access to the drug for patients who may benefit.”
Dr. Howard L. Kaufman, President and CEO at Ankyra added “I am delighted to welcome Dr. Butchko and Ms. Withington to the Ankyra Board of Directors. They bring valuable expertise to the company and will add diversity and new perspectives on our goal of advancing the research and development of our anchoring platform and our commitment to doing so in a patient-focused manner.” Ankyra’s lead asset, ANK-101, is an anchored IL-12 that entered phase I clinical trials earlier this year and now over 10 patients with advanced solid cancers have been treated at multiple study sites in the United States and Canada (NCT:06171750).
About Ankyra Therapeutics
Ankyra Therapeutics is a biotechnology company that has developed a highly differentiated technology platform that expands the therapeutic window of cytokine drugs by forming a stable depot in the tumor after local administration leading to prolonged immune activation and potent local and systemic immunity with reduced systemic toxicity. Ankyra was founded in 2019 and is headquartered in Cambridge, Massachusetts. For more information, please visit www.ankyratx.com
Contacts
For Investor Inquiries:
Howard L. Kaufman, MD
President and CEO
Ankyra Therapeutics
info@ankyratx.com
For Media Inquiries:
Noah Oshry
Head of Business Operations
noshry@ankyratx.com
